Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)
By J. D. de Souza, Bonnie J. Yap, K. Wroblewski, Victoria S Blinder, Fabiana S. Araújo, F. Hlubocky, L. Nicholas, Jeremy O'Connor, B. Brockstein, M. Ratain and 2 more. Cancer, 2016
802 citations recorded by the source corpus.
Cancer and its treatment lead to increased financial distress for patients. To the authors' knowledge, to date, no standardized patient‐reported outcome measure has been validated to assess this distress.
Subfields: Forestry, Plant Science
View Paper: https://www.semanticscholar.org/paper/59dc21683e073f2434443ac1d0215f111a557f6a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Pricivel M Carrera
- H. Kantarjian
- V. Blinder
Citations in the corpus
- The Financial Burden and Distress of Patients with Cancer: Understanding and Stepping-Up Action on the Financial Toxicity of Cancer Treatment (2018, methodology): “The pilot study by Zafar et al 48 on OOP expenses and the experience of insured patients with cancer, coupled with validation of the COmprehensive Score for financial Toxicity (COST) measure as a clinically relevant, patientcentered tool to measure financial toxicity, serves as a foundation for buil”